Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.

J Clin Oncol
Authors
Keywords
Abstract

Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy with a remarkably heterogeneous course, ranging from indolent disease with no need for immediate therapy to rapidly progressive disease associated with therapeutic resistance. The recent US Food and Drug Administration approvals of novel targeted therapies such as inhibitors of B-cell receptor signaling and B-cell lymphoma 2 have opened up new opportunities in the clinical management of patients with CLL and heralded a new era in the clinical treatment of this disease. In parallel, the implementation of novel sequencing technologies has provided new insights into CLL complexity, identifying a growing list of putative drivers that underlie inter- and intratumor heterogeneities in CLL affecting disease progression and resistance. The identification of these novel genomic features that can indicate future drug resistance or guide therapeutic management is now becoming a major goal in CLL so that patients can best benefit from the increasingly diverse available therapies, as discussed herein.

Year of Publication
2017
Journal
J Clin Oncol
Volume
35
Issue
9
Pages
984-993
Date Published
2017 Mar 20
ISSN
1527-7755
DOI
10.1200/JCO.2016.71.0822
PubMed ID
28297623
PubMed Central ID
PMC5559883
Links
Grant list
R01 CA184922 / CA / NCI NIH HHS / United States